ML115
Based on 8 publication(s) in Google Scholar
ML115, a molecular probe of the signal transducer, is a selective STAT3 agonist, with an EC50 of 2 nM. ML115 increases the expression of BCL3, a known STAT3-dependent oncogene. ML115 is inactive against the related STAT1, STAT5 and NF-κB anti-targets. ML115 counteracts the effects of Ginsenoside Rc (HY-N0042) on cell viability and inflammatory responses in LPS (HY-D1056)-stimulated H9c2 and RAW264.7 cells, while altering oxidative stress markers. ML115 can be used for the study of breast and prostate cancers.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.98%
- CAS No.: 912798-42-6
- Formule: C15H15ClN2O4
- Masse moléculaire:322.74
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Highly Selective Activators Library
HY-L159
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) ML115
More- Imeta. 2026 Jun 14.
- Cell Host Microbe. 2026 Feb 11;34(2):245-262.e8. [Abstract]
- Eur J Pharmacol. 2025 Apr 9:177606. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 May 8:167893. [Abstract]
- Basic Clin Pharmacol Toxicol. 2025 Dec;137(6):e70135. [Abstract]
- Discov Oncol. 2026 Jun 3. [Abstract]
- J Mol Histol. 2025 Apr 28;56(3):148. [Abstract]
- bioRxiv. 2025 January 31.
Activité biologique
|
Stat-3 2 nM (EC50) |
ML115 (10 µM, 48 h) reverses the Ginsenoside Rc (HY-N0042)-induced improvement in viability of LPS (HY-D1056)-stimulated H9c2 cells, increases MDA levels, and decreases SOD and GSH-Px activities[1].
ML115 (10 µM, 6 h) reverses the Ginsenoside Rc-induced downregulation of IL-1β, TNF-α, iNOS and COX2, and upregulation of Arg1 and Ym1 in LPS-treated RAW264.7 cells, and also reverses the Ginsenoside Rc-induced reduction in IL-1β and TNF-α production[1].
ML115 exhibits no cytotoxicity in HT-1080 and NIH-3T3 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LPS-treated RAW264.7 cells
-
Concentration:10 µM
-
Incubation Time:6 h
-
Result:Reversed the Ginsenoside Rc-induced downregulation of IL-1β, TNF-α, iNOS and COX2, and upregulation of Arg1 and Ym1 in LPS-treated macrophages.
Chemical Information
-
CAS No. 912798-42-6
-
Appearance Solid
-
Masse moléculaire 322.74
-
Formule C15H15ClN2O4
-
Color White to off-white
-
SMILES
O=C(C1=NOC(C2CC2)=C1)NC3=CC(OC)=C(Cl)C=C3OC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
-
Cell Host Microbe
Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. [Abstract]2026 Feb 11;34(2):245-262.e8. PMID: 41605216 -
Eur J Pharmacol
Carnosol inhibits influenza A virus by disrupting the viral envelope and interfering with Jak2/STAT3 signaling pathway. [Abstract]2025 Apr 9:177606. PMID: 40216182 -
Biochim Biophys Acta Mol Basis Dis
HNF-1α promotes urethral fibrosis by up-regulating STAT3 transcriptional activity in mice hypospadias. [Abstract]2025 May 8:167893. PMID: 40348066 -
Basic Clin Pharmacol Toxicol
Bergaptol Alleviates Oxidative Stress and Inflammation in Intracerebral Haemorrhage Mice via JAK2/STAT3 and NF-κB Pathways, Improving Neurological Function. [Abstract]2025 Dec;137(6):e70135. PMID: 41139697 -
Discov Oncol
PSMC2 drives tumor progression in nasopharyngeal carcinoma by inhibiting ferroptosis through STAT3. [Abstract]2026 Jun 3. PMID: 42234270 -
J Mol Histol
STAT3/FoxO3a/Sirt1 pathway inhibition by ginsenoside Rc ameliorates cardiomyocyte damage in septic cardiomyopathy by altering macrophage polarization. [Abstract]2025 Apr 28;56(3):148. PMID: 40293549 -
Solvant et solubilité
DMSO : 20 mg/mL (61.97 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Jinzhong Wang MS, et al. STAT3/FoxO3a/Sirt1 pathway inhibition by ginsenoside Rc ameliorates cardiomyocyte damage in septic cardiomyopathy by altering macrophage polarization. J Mol Histol. 2025 Apr 28;56(3):148. [Content Brief]
[2]. Madoux F, et al. Modulators of STAT Transcription Factors for the Targeted Therapy of Cancer (STAT3 Activators). 2009 Aug 27 [updated 2010 Dec 16]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0985 mL | 15.4923 mL | 30.9847 mL | 77.4617 mL |
| 5 mM | 0.6197 mL | 3.0985 mL | 6.1969 mL | 15.4923 mL | |
| 10 mM | 0.3098 mL | 1.5492 mL | 3.0985 mL | 7.7462 mL | |
| 15 mM | 0.2066 mL | 1.0328 mL | 2.0656 mL | 5.1641 mL | |
| 20 mM | 0.1549 mL | 0.7746 mL | 1.5492 mL | 3.8731 mL | |
| 25 mM | 0.1239 mL | 0.6197 mL | 1.2394 mL | 3.0985 mL | |
| 30 mM | 0.1033 mL | 0.5164 mL | 1.0328 mL | 2.5821 mL | |
| 40 mM | 0.0775 mL | 0.3873 mL | 0.7746 mL | 1.9365 mL | |
| 50 mM | 0.0620 mL | 0.3098 mL | 0.6197 mL | 1.5492 mL | |
| 60 mM | 0.0516 mL | 0.2582 mL | 0.5164 mL | 1.2910 mL |
ML115 Related Classifications
HY-111152 Related Classifications
Powered by Bioz